AGIO Agios Pharmaceuticals, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AGIO Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$26.53
Analyst Target
$36.75
+38.5%
Upside
52W High
$46.0
52W Low
$22.24
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 07, 2026
Market cap
$1.55B
P/E
N/A
ROE
-27.6%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
87%
Analysis Accuracy
AGIO's deterministic health scores are severely weak, with a Piotroski F-Score of 0/9 indicating extreme financial distress and no Altman Z-Score available, which raises significant bankruptcy risk. Despite strong revenue growth of 43.7% YoY, the company reports a 0.00% profit margin, negative operating margin of -907.37%, and negative ROE of -27.57%, signaling deep operational inefficiency. Insider selling activity over the past six months, totaling $1.17M in sales, reflects bearish sentiment from leadership. The stock trades at a premium valuation (Price/Sales of 34.54) with no earnings or cash flow support, and its 52-week price decline of 52.5% underscores deteriorating market confidence.
Key Strengths
Strong revenue growth of 43.7% YoY indicates market traction and product demand
Low debt/equity ratio of 0.03 suggests minimal leverage risk
High current and quick ratios (13.82 and 12.81) indicate strong short-term liquidity
Recent quarterly earnings have shown some positive surprises (e.g., +13.9%, +11.9%)
Analyst target price of $36.75 implies upside potential, though consensus is absent
Key Risks
Piotroski F-Score of 0/9 signals severe financial distress and poor operational health
Negative operating margin (-907.37%) and zero profit margin indicate unsustainable business model
Insider selling by CEO, CFO, and officers totaling $1.17M in six months reflects bearish sentiment
No positive intrinsic value or Graham Number, and forward P/E of -4.03 indicates unprofitability
Stock has declined 52.5% over 5 years and 22.9% over 1 year, indicating persistent underperformance
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
20
55
30
15
0
AI Verdict
Weak
Key drivers: Piotroski F-Score of 0/9, Negative operating and net margins, Insider selling, No intrinsic value, High valuation relative to earnings
Confidence
85%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 34.54 may reflect high growth expectations
Watchpoints
- No Graham Number or intrinsic value
- Forward P/E of -4.03 indicates no earnings
- Price/Sales is extremely high for a non-profitable firm
- No cash flow or earnings to support valuation
Future
55/100
Ref Growth rates
Positives
- 43.7% YoY revenue growth suggests strong top-line momentum
- Recent quarters show positive earnings surprises (e.g., +13.9%, +11.9%)
Watchpoints
- Negative earnings growth (-21.1% YoY)
- No free cash flow or operating cash flow data
- Forward P/E negative, indicating continued losses
Past
30/100
Ref Historical trends
Positives
- Consistent revenue growth over multiple quarters
- Some quarters beat estimates (2/4 in last 4)
Watchpoints
- Historical earnings have been volatile and negative
- One quarter showed a -118.5% surprise (2024-10-31)
- 5-year price decline of 52.5% reflects long-term underperformance
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely low debt/equity (0.03)
- High current and quick ratios (13.82, 12.81)
Watchpoints
- Piotroski F-Score of 0/9 indicates financial distress
- No Altman Z-Score available, but F-Score of 0 implies high bankruptcy risk
- Negative ROE (-27.57%) and ROA (-18.71%)
- Operating margin of -907.37% is unsustainable
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$26.53
Analyst Target
$36.75
Upside/Downside
+38.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AGIO and closest competitors.
Updated 2026-02-06
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
Primary
|
-52.5% | -14.2% | -22.9% | -25.8% | -7.0% | -3.3% |
|
ACHC
Acadia Healthcare Company, Inc.
Peer
|
-67.8% | -79.3% | -59.8% | -20.1% | +43.0% | +25.4% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
ATAI
AtaiBeckley Inc.
Peer
|
-78.7% | +117.3% | +174.8% | +16.2% | -0.9% | +14.0% |
|
ALVO
Alvotech
Peer
|
-53.0% | -55.7% | -59.9% | -45.3% | -0.6% | +6.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.03
PEG Ratio
N/A
P/B Ratio
1.2
P/S Ratio
34.54
EV/Revenue
14.26
EV/EBITDA
-1.36
Market Cap
$1.55B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-907.37%
Gross Margin
N/A
ROE
-27.57%
ROA
-18.71%
Growth
Revenue and earnings growth rates
Revenue Growth
+43.7%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
13.82
Strong
Quick Ratio
12.81
Excellent
Cash/Share
$16.34
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-12
$N/A
2025-10-30
$-1.78
+6.5% surprise
2025-07-31
$-1.93
-10.0% surprise
2025-05-01
$-1.55
+11.9% surprise
Healthcare Sector Comparison
Comparing AGIO against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-27.57%
This Stock
vs
-56.84%
Sector Avg
-51.5%
(Below Avg)
Debt to Equity
0.03
This Stock
vs
2.68
Sector Avg
-98.7%
(Less Debt)
Revenue Growth
43.7%
This Stock
vs
61.93%
Sector Avg
-29.4%
(Slower)
Current Ratio
13.82
This Stock
vs
3.47
Sector Avg
+298.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.55B | - | -27.6% | -% | $26.53 | |
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $1.52B | 13.75 | 3.7% | 3.3% | $16.77 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | |
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.51B | - | -100.8% | -% | $4.15 | |
|
ALVO
Alvotech
|
BEARISH | $1.64B | 22.87 | -% | 12.1% | $5.26 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-05 | MILANOVA TSVETA | Officer | Stock Award | 8,475 | - |
| 2026-01-05 | MILANOVA TSVETA | Officer | Sale | 2,872 | $77,601 |
| 2025-12-30 | BURNS JAMES WILLIAM | Officer | Stock Award | 6,000 | - |
| 2025-12-30 | MILANOVA TSVETA | Officer | Stock Award | 6,000 | - |
| 2025-12-30 | JONES CECILIA | Chief Financial Officer | Stock Award | 6,000 | - |
| 2025-12-30 | GHEUENS SARAH | Officer | Stock Award | 6,000 | - |
| 2025-12-30 | GOFF BRIAN | Chief Executive Officer | Stock Award | 38,278 | - |
| 2025-12-30 | JONES CECILIA | Chief Financial Officer | Sale | 2,932 | $79,428 |
| 2025-12-30 | GOFF BRIAN | Chief Executive Officer | Sale | 18,703 | $506,664 |
| 2025-12-30 | GHEUENS SARAH | Officer | Sale | 2,932 | $79,428 |
| 2025-12-30 | BURNS JAMES WILLIAM | Officer | Sale | 2,932 | $79,428 |
| 2025-12-30 | MILANOVA TSVETA | Officer | Sale | 2,932 | $79,428 |
| 2025-11-12 | SCADDEN DAVID T. | Director | Option Exercise | 200 | $3,618 |
| 2025-11-12 | SCADDEN DAVID T. | Director | Sale | 200 | $8,768 |
| 2025-11-11 | GHEUENS SARAH | Officer | Option Exercise | 2,454 | $61,375 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
8 analysts
JP Morgan
2026-01-06
Neutral
Neutral
Leerink Partners
2025-12-26
Outperform
Outperform
Truist Securities
2025-12-24
Buy
Buy
B of A Securities
2025-12-24
Buy
Buy
HC Wainwright & Co.
2025-12-24
Buy
Buy
Citigroup
2025-11-26
Buy
Truist Securities
2025-11-24
Buy
JP Morgan
2025-11-21
Neutral
Neutral
RBC Capital
2025-11-20
Outperform
Sector Perform
B of A Securities
2025-11-20
Buy
Buy
Past News Coverage
Recent headlines mentioning AGIO from our newsroom.
Newest → oldest
No matching news yet.